Yesterday, I couldn’t stand being inside my skin. It felt like a prison, this body of mine that didn’t know what it wanted or why it was here. I squirmed through the day, fussing and eating and eating ...
Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.
Bipolar disorder exists on a spectrum rather than as a single, uniform condition. This fundamental characteristic explains why two people with the same diagnosis can experience dramatically different ...
The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.
FDA approves evidence-based tool (Bysanti) to address severe mood and psychotic symptoms, which may predict future indications.
Vanda Pharmaceuticals VNDA shares are trading higher during the premarket session on Monday following the announcement of FDA ...
A Swedish study of over two million individuals introduced “genetic specificity,” quantifying how much psychiatric genetic ...
An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...
The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results